TABLE 3.
Serologic reactivity of anti-Sc antibodies
| Red cell phenotype | Antibody titer (number of individuals, if >1) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Sc3 | Anti-SCAR | ||||||||||
| Red cells | By sequencing | By serologya | Anti-Scl | Untreated | Papain treated | DTT treated | Trypsin treated | Untreated | Papain treated | DTT treated | Trypsin treated |
| Patient | SC:l,−2,3,−4,5,6,7,−8 | SC:1,3 | 8 | 128 | 64 | 64 | 8 | - | - | - | - |
| Sister 1b | SC:1,−2,3,−4,5,6,7,8 | SC:1,3,−4 | 4 | 32 | - | - | - | 1 | 2 | 0 | 0 |
| Sister 2b | SC:l,−2,3,−4,5,6,7,8 | SC:1,3 | 4 | 64 | - | - | - | 4 | 2 | 2 | 0 |
| Controls | - | SC:1,3,−4 | 4 (3) | 32–64 (3) | 32–64 (3) | 32–64 (3) | 16–32 (3) | 4 (2) | 4 (4) | 2 (1) | 0 (1) |
| Rd+ control | - | SC:1,3,4 | 2 | 32 | NT | NT | NT | 1 | 4 | 0 | 0 |
Abbreviation: -, not tested.
a
All red cells were Fy(a-b+) and DAT negative; Radin (Sc4) testing not done in the patient and sister 2 because of ABO incompatibility.
b
Heterozygous for SCAR (Sc8) by sequencing.